

Synthetic Chemistry for the Chemical Modification of Polyfunctional Biopolymers as Antimicrobial Nanomaterials

2 November 2022, CSIR International Convention Centre

Zamani Cele



science & innovation

Department:
Science and Innovation
REPUBLIC OF SOUTH AFRICA



Why is there a crisis? Issues with small molecules

- We currently lack good “pipeline drugs” and designing novel or new antibiotics is increasingly more challenging.
- Research and development of new antibiotics can be risky and scientifically challenging
- Covid-19 Pandemic


GLOBAL

A failure to address the problem of antibiotic resistance could result in:



10m
deaths
by 2050

Costing
£66
trillion



SA hospitals face worrying rise in drug-resistant bacteria and

‘superbugs’

06 Jan 2022




Culled from The Lancet



CSIR
Touching lives through innovation

1. Nanoantibiotics”: A New Paradigm for Treating Infectious Diseases using Nanomaterials in the Antibiotics Resistant Era. J. of Control. Release. 156, 128-145 (2011).
2. The Review on Antimicrobial Resistance Chaired by Jim O’Neill, 2016

Biopolymers as alternatives to small molecules - Sources




Possible Applications

- Antiadhesion materials
- Binding materials
- Bone-setting materials
- Hemostatic materials
- Drug delivery system
- Synthetic skin
- Wound management
- Artificial tendon and ligament


Resistance :

There are no reports of resistance to date. Lack of acquired resistance is likely due to multimodal antimicrobial.

Chitosan – Properties and antimicrobial potential





Obtaining chitosan by the deacetylation alkaline treatment of chitin from shrimp shell wastes



Properties affecting physicochemical characteristics of chitosan:

- Molecular weights (MWs) and MW distributions, chain lengths, degrees of deacetylation, charge densities and charge distributions, salt-forms, viscosities, and water retention values.
- Chitosan can also be modified to improve its properties.

Protection/Deprotection Chemistry - Synthesis and antimicrobial activity of O-Allyl quaternary chitosan







Size = 100 – 500 nm


	Bacteria	2a	3a	3b	Chitosan	Tetracycline	Ampicillin
1	<i>S. sanguinis</i> ATCC 10556	64	128	64	>512	<4	32
2	<i>S. aureus</i> ATCC 29213	64	>512	64	512	<4	<4
3	<i>S. epidermidis</i> ATCC 12228	64	512	64	>512	32	16
4	<i>Strep mutants</i> ATCC25175	>512	>512	>512	>512	32	<4
5	<i>L. rhamnosus</i> ATCC 7469	>512	>512	>512	>512	<4	<4

- The introduction of both cationic and hydrophobic moieties into the polymers improves the interaction with bacterial cells, leading to irreparable membrane damage and bacterial death.

Synthesis of fluorinated chitosan derivatives





High contact angle droplet





¹⁹F NMR Spectrum of Fluorinated Chitosan (41% Degree of Substitution)

Synthesis of fluorinated quaternary chitosan derivatives



Degree of quaternization (DQ):
 Determined by using Mohr's
 titration


Antimicrobial assay



<http://pubs.acs.org/journal/acsodf>

Fluorinated Quaternary Chitosan Derivatives: Synthesis, Characterization, Antibacterial Activity, and Killing Kinetics

Zamani E.D. Cele, Anou M. Somboro, Daniel G. Amoako, Lindokuhle F. Ndlandla, and Mohammed O. Balogun*





Quaternary chitosan antiviral inhibition against SARS-Cov-2




Masks

SARS-CoV-2





- Immobilizing polycations on various surfaces has been shown to convey antiviral properties for both enveloped and non-enveloped viruses.
- SARS-CoV-2 virus-capture onto uncoated (A1-3) and coated (AC1-3) masks.

Applications of antimicrobial functional materials



- a) Emerging antimicrobial pathogens
- b) Antimicrobial mechanism against the pathogens.
- (c) Antimicrobial coatings for various applications

Chitosan-based nanomaterials as potential electrolytes



Particle size and surface charge of Chitosan derivatives in various aqueous diluents.

Material	Diluent	Particle size (nm)	Surface charge
LA-CS-Suc	dH2O	320	-20.77
LA-CS-Suc	PBS	216	-14.93
LA-CS-Suc	NaCl	257	-12.47
LA-CS	4% acetic acid	371	19.3
CS 10kDa	1% acetic acid	1078	26.93


These could find applications in health systems where charged delivery systems are required for tissue-specific delivery of bioactives.

Biopolymer-based materials in nanomedicine



- Combining small-molecule medicines with polymers could offer big rewards for pharmaceutical researchers.
- The theory is sound: you take a conventional small-molecule medicine and then attach it to a polymer and you get a new drug (a polymer-drug conjugate) that will have a longer *in vivo* plasma half-life than the drug alone.

Simple medicines: small-molecule polymer therapeutics



Malaria



Global policies highlight the need to end malaria infections: Millennium Development Goals (MDG) and Sustainable Development Goals (SDG)



Sustainable Development Goals

•Target 3.3: "By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases."



Our approach is to introduce modern therapeutic technologies – the parasite is a timeless master of adaptation.

Malaria is an ancient disease still being treated with ancient drugs. *Quinine* (in use for over 4 centuries), the *artemisinins* (from Chinese folk medicine), *chloroquine* (>80 years); *primaquine* (>60 years).

Issues concerning drug solubility, biostability, toxicity, and uncontrolled pharmacokinetics can be overcome with adequately designed drug NCs based on liposomes, polymers or dendrimers. Furthermore, drug resistance evolves when one cannot deliver to the parasites a sufficiently high dose to kill them rapidly.

One major unmet clinical need in treatment: *No combination of drugs suitable for intravenous treatment of severe malaria currently exists.*


Conjugation of lumefantrine to a multi-valent polymer



Size of polymer-drug conjugate = ~90 nm

What have we achieved?


Development



IV Formulation



PK/PD



Conclusions and future developments



- Modifications are often performed in order to improve the properties of biopolymers to suit them for different applications.
- It is important to understand the Mechanism of Action and Structure-Activity Relationship (SAR).
- We need to focus on studying the durability of biopolymers for numerous applications and discover novel processing techniques.

Acknowledgments



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA



CSIR Clusters:
Chemicals & Next-Gen Health



THANK YOU